Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300 patients age 18-55 presenting to the emergency department with chief complaint of nausea or vomiting will be enrolled from February 2021 - February 2022. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
60
2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP
Ondansetron
Bronson Methodist Hospital
Kalamazoo, Michigan, United States
Visual Analog Scale (VAS)
Mean change in visual analog scale (VAS) of self-rated nausea severity
Time frame: from enrollment to 30, 60, and 90 minutes after drug administration
Analgesia
Measurement of analgesia graded based on a self-reported validated 10 point visual analog scale (VAS)
Time frame: 0, 30, 60, 90 minutes
Efficacy in marijuana users
Marijuanna use will be documented and quantified
Time frame: Baseline (time 0)
QT prolongation
QT will be measured on the cardiac monitor
Time frame: Baseline (time 0) and 90 minutes
Incidence of side-effects
Inquiry about side effects
Time frame: 0, 30, 60, 90 minutes and 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.